Navigation Links
Watson Announces Commencement of Secondary Offering by Selling Stockholder
Date:11/10/2010

MORRISTOWN, N.J., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the underwritten public offering of 10,537,755 shares of its common stock held by Quiver, Inc. pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission (the "Offering") on August 17, 2009. The selling stockholder acquired its shares of Watson common stock in connection with Watson's acquisition of the Arrow Group. Watson will not receive any proceeds related to the Offering, and its total number of shares of common stock outstanding will not change as a result of the Offering.

J.P. Morgan Securities LLC is acting as sole book-running manager and underwriter for the Offering.

A prospectus supplement relating to the Offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and the accompanying base prospectus relating to the Offering may be obtained, when available, by mail from: J.P. Morgan Securities LLC, Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717, or by phone at (866) 803-9204. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

Forward-Looking StatementStatements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended September 30, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.CONTACTS:Investors:Patty Eisenhaur(973) 355-8141Media:Charlie Mayr(973) 355-8483(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO)


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson To Present At The 2010 Credit Suisse Healthcare Conference
2. Watson Confirms Crestor® Patent Challenge
3. Watsons Generic Version of Lotrel ® Receives FDA Approval
4. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings
5. Watson Reaches Settlement with Endo Over Opana® ER
6. Watson Confirms Azilect® Patent Challenge
7. Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference
8. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
9. Watson to Present at the Bank of America/Merrill Lynch Global Healthcare Conference
10. Watsons Generic Yasmin® Receives FDA Approval
11. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... ... financial consultations to communities in northern Virginia and DC, is announcing a cooperative ... for patients with Alzheimer’s and other disorders that lead to memory impairment. , ...
(Date:6/27/2017)... , ... June 27, 2017 , ... DrugDev ... is whether they can trust the sponsor to pay them correctly and on time. ... and CROs establish payment strategies that encourage sites to work on their studies. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the ... Louisiana became the sixth state to pass legislation which ensures that children can ... signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington who ...
(Date:6/27/2017)... ... 2017 , ... The Kelahan Agency, a privately owned firm ... southern New Hampshire, is teaming up with the New Horizons for New Hampshire ... the region. , New Horizons for New Hampshire provides a wealth of services ...
(Date:6/27/2017)... Monroe, CT (PRWEB) , ... June 27, 2017 , ... ... announce the recent renovation of his practice, Advanced Periodontics and Dental Implant Center of ... and increased the administrative and waiting areas. The renovations are intended to improve patient ...
Breaking Medicine News(10 mins):